Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRS3123 vs Vancomycin in Clostridioides Difficile Infection
NCT04781387Phase 2Completed
- Sponsor
- Crestone, Inc.
- Start
- Jan 2021
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of crs-3123 in Clostridioides difficile infection (CDI), sponsored by Crestone, Inc.. Started Jan 2021; status: completed.
02
Drugs
crs-3123
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT04781387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04781387.